



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/663,872	09/16/2003	Liliana Tejidor	00825Div.JAR	3114
7590	05/15/2007	Judith A. Roesler, Esq. BioMerieux, Inc. Patent Department 100 Rodolphe Street Durham, NC 27712	EXAMINER	
		CHEU, CHANGHWA J		
		ART UNIT		PAPER NUMBER
		1641		
		MAIL DATE		DELIVERY MODE
		05/15/2007		PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

TH

Office Action Summary	Application No.	Applicant(s)	
	10/663,872	TEJIDOR ET AL.	
	Examiner	Art Unit	
	Jacob Cheu	1641	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 21 February 2007.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 101-110 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 101-110 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All b) Some * c) None of:
1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____ | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Applicant's amendment filed on 2/21/2007 has been received and entered into record and considered.

The following information provided in the amendment affects the instant application:

1. Claim 1-100 cancelled.
2. Claims 101-109 are under examination.

Double Patenting

1. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

2. Claims 101-103, 105-110 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claim1-4, 7-9, 12-16, 21-27, 39-41, 46- 51 of U.S. Patent No. 6645768. Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant invention directs to a kit for assessing hemostatic potential of a patient to differentiate hyper, normal and hypocoagulable plasma comprising a coagulation activator ranging from 3-10 picomolar, and a second thrombomodulin ranging from 5-20 nanomolar, and further comprising phospholipids vesicles ranging from 100-150 micromolar and a metal salt in an amount of 5 to 50 mM, where all the recited features are encompassed and within the ranges of the mentioned claims of US 6645768.

Claim Objections

3. Claim 105 is objected to because of the following informalities: “said tissue factor” should be rewording as “said coagulation activator” for consistency with claim 101. Appropriate correction is required.

4. Claims 106 is objected to because of the following informalities: line 8, “ from a patient treated with either an inhibitor *or* the tissue factor pathway” should be rewording as “from a patient treated with either an inhibitor *of* the tissue factor pathway. Appropriate correction is required.

Response to Applicant’s Arguments

5. The rejection under Hawkins et al. (US 5625036) are withdrawn because the assay taught by Hawkins et al. cannot be used to differentiate multiple alternations, i.e. hypercoagulability.

Allowable Subject Matter

6. Claims 101-110 are allowable. The following is an examiner's statement of reasons for allowance: no prior art teaches nor suggests a reagent for an assay to determine a hemostatic potential of a blood or plasma sample comprising a coagulation activator wherein the coagulation activator is present at a concentration level to trigger thrombin formation fibrin polymerization but not sufficient to result in a complete fibrin polymerization of said blood or plasma sample and a second thrombomodulin wherein said reagent may be utilized to assess a hypocoaguable, normal, and hypercoaguable condition in a single assay. The closest prior art is Hawkins et al. (US 5625036) where the reference only teaches a reagent for assessing coagulant activity, i.e. hypocoagulation in the patient. Hawkins et al. can be distinguished from the instant invention because the instant invention recites a reagent capable of assessing *all* hypocoagulation, normal and hypercoagulation in a single assay.

Conclusion

7. No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jacob Cheu whose telephone number is 571-272-0814. The examiner can normally be reached on 9:00-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long Le can be reached on 571-272-0823. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1641

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.



Jacob Cheu

Examiner

Art Unit 1641

May 7, 2007